Abstract: The disclosure discloses a biomarker in osteoporosis intervention therapy by bone peptide, the biomarker including a lipid and lipid-like molecule, an organic acid and its derivative, and/or a neurotransmitter, wherein the lipid and lipid-like molecule includes one or more of taurine, arachidonic acid, 1-palmitoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine, (4Z, 7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-docosahexaenoic acid, 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphocholine, taurodeoxycholic acid, taurochenodeoxycholate or taurocholic acid. The disclosure discloses a screening method of a biomarker in the anti-osteoporosis activity of bone peptide. The disclosure discloses a use of the biomarker.